Cerebrovascular Accident, Hypercholesterolemia
Conditions
Brief summary
The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.
Interventions
DRUGAtorvastatin
Sponsors
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* clinically defined lacunar syndrome 3 months before inclusion * small deep infarct on diffusion MRI (Diffusion Weighted Imaging) * no atherothrombotic, cardio-embolic, or other rarer cause.
Exclusion criteria
* patients with past coronary event * contra-indication for assessment of vasomotor reactivity * patients being on statin therapy at the time of brain infarction * contra-indication for statin therapy * patient still under statin therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients. CVR, humeral and carotid vasoreactivity will be measured in all patients at M0 and M3. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on endothelium dependant and independent vasomotoricity of humeral and / or common carotid artery (according to validation study) in lacunar patients. | — |
Countries
France
Outcome results
None listed